Novonate culminated its journey in developing products for neonates in intensive care after acquisition by Laborie. Through the acquisition, Laborie aims to address an unserved need in neonatal intensive care units with Novonate’s LifeBubble technology, a device which increases umbilical catheter protection and safety.
MedTech Venture Partners (MTVP), the venture fund arm of UCSF Rosenman Institute, invested in the early days and throughout the Novonate journey. This led to Novonate CEO, Eric Chehab, to take the Founders Pledge—a pay-it-forward commitment for future healthcare innovators who in return receive resources that empower health technology innovators to deliver transformative solutions that improve lives.
“Rosenman Institute’s deep understanding and commitment to our products have been instrumental in our success. From the intern program to expert advisors, they provided the resources we needed to support our journey in developing products for neonates in intensive care,” reflected Chehab. “Through Rosenman Institute’s affiliated fund–MTVP, we not only secured crucial funding but also gained access to a team with years of operational experience. This support has been immeasurable in our pursuit of innovative solutions that improve clinical outcomes for babies around the world. We are grateful for Rosenman’s unwavering belief in our mission, and for their ongoing partnership in our efforts to make a difference.”
Read the full press release here.